immunogen inc (IMGN) Key Developments
Immunogen, Inc. Releases CD37-Targeting ADC, IMGN529
Jun 17 15
ImmunoGen, Inc. announced the first presentation of findings with the company’s CD37-targeting ADC, IMGN529, in combination with the CD20-targeting antibody, rituximab (Rituxan), in preclinical assessments. These data are being presented in a poster at the 13thInternational Conference on Malignant Lymphoma taking place in Lugano, Switzerland. Among the findings being presented are: IMGN529 exhibits strong synergy with rituximab and other CD20-targeting antibodies in cell lines representative of an array of non-Hodgkin lymphoma (NHL) subtypes, including both GCB and ABC diffuse large B-cell lymphoma (DLBCL); Consistent with the in vitro findings, the combination of IMGN529 and rituximab was highly active against DLBCL models in vivo; Synergy also was seen in vitro in amodel representative of “double hit” lymphoma, a particularly difficult-to-treat type of DLBCL characterized by deregulation of two different genes, BCL2 (or BCL6) and MYC; and Both IMGN529’s antibody component and its DM1 payload contributed to its synergistic activity with rituximab.
ImmunoGen, Inc. Announces Data from Phase I Ovarian Cancer Trial
Jun 11 15
ImmunoGen, Inc. has announced data from a Phase I trial with FRá-targeting antibody-drug conjugate, or ADC, mirvetuximab soravtansine, in patients with platinum-resistant ovarian cancer. The findings reported are from an ongoing Phase I trial. Once the recommended Phase II dose (RP2D) of mirvetuximab soravtansine was established during dose finding, an expansion cohort was opened to assess the safety and activity of this ADC specifically in the treatment of patients with FRá-positive platinum-resistant ovarian cancer. Approximately 80% of the patients screened have met the criteria for having FRá-positive disease. Twenty-two patients were included in the analysis =- two from the dose-escalation phase of the trial and the twenty enrolled in the expansion cohort at the time of data cutoff for presentation. All had FRá-positive platinum-resistant ovarian cancer and had received mirvetuximab soravtansine at the RP2D (6.0 mg/kg, given every three weeks). All had previously received taxane as well as platinum therapy. Thirteen were still on study at the time of data cutoff. The majority of adverse events reported were low grade (grade 1 or 2), with diarrhea, blurred vision, nausea, vomiting, fatigue, and abdominal pain the most common treatment-emergent events reported (> 20% of patients). Seventeen of the 22 patients were included in the efficacy analysis; the other five patients were still on study and had not yet reached their first assessment. Nine of these 17 patients had an objective response (8 partial responses, 1 complete response) to treatment, for an ORR of 53%. The responses in six of these nine patients were ongoing at the time of data cutoff, with five of these six patients on treatment for more than 15 weeks. The findings are from a Phase I trial assessing mirvetuximab soravtansine for the treatment of FRá-positive solid tumors. After the RP2D was established in patients likely to have FRá-positive disease using a once every 3-week dosing schedule, an expansion cohort was opened to evaluate the ADC specifically in patients with FRá-positive platinum-resistant ovarian cancer when administered as a single agent at this RP2D. To be eligible for enrollment in this expansion cohort, patients must have ovarian cancer that responded to primary platinum therapy, but then progressed within six months or progressed on or within six months of treatment with subsequent platinum therapy. The cancer also must be FRá-positive, assessed by immunohistochemistry. Approximately 80% of patients screened met this criteria based on the CLIA lab assay. This expansion cohort has been expanded from 20 to 40 patients to obtain additional experience in this patient population.
ImmunoGen, Inc. Presents at Sachs Immuno-Oncology: BD&L and Investment Forum, May-29-2015 09:50 AM
May 17 15
ImmunoGen, Inc. Presents at Sachs Immuno-Oncology: BD&L and Investment Forum, May-29-2015 09:50 AM. Venue: Hyatt Chicago Magnificent Mile, Chicago, Illinois, United States. Speakers: Richard J. Gregory, Chief Scientific Officer and Executive Vice President of Research.
ImmunoGen, Inc. Announces Clinical Data Presentations at Upcoming ASCO Annual Meeting
May 13 15
ImmunoGen, Inc. provided information on ImmunoGen-related presentations to take place at the 2015 American Society of Clinical Oncology (ASCO) annual meeting being held May 29-June 2 in Chicago, IL. ImmunoGen’s mirvetuximab soravtansine is the first ADC to target folate receptor alpha (FRa), which is highly expressed on many ovarian cancers and on other types of solid tumors. The ASCO presentations will be on the initial findings from the Phase I expansion cohort assessing this ADC as a single agent for the treatment of patients with FRa-positive platinum-resistant ovarian cancer (abstract #5518) and the dose-finding results to date with a weekly dosing schedule compared with a once every three week schedule (abstract #5558). Abstract #5518: Title: “Preliminary single agent activity of IMGN853, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Phase I trial. Gynecologic Cancer Poster Session: May 30, 1:15-4:45pm CT (S Hall A, Board #76), followed by oral discussion with highlights during the Gynecologic Cancer Poster Discussion Session 4:45-6:00pm CT (E354b). Abstract #5558: Title: Phase 1 study of IMGN853, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC) in patients (Pts) with epithelial ovarian cancer (EOC) and other FRA-positive solid tumors. Gynecologic Cancer Poster Session: May 30, 1:15-4:45pm CT (S Hall A, Board #116). There will be several presentations on Roche’s Kadcyla® (ado-trastuzumab emtansine), which uses ImmunoGen’s ADC technology, including one on the data from the MARIANNE Phase III trial (Abstract #507). Title: “Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study. Breast Cancer Oral Abstract Session: June 1, 10:12-10:24am CT (N Hall B1).
ImmunoGen, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 11:00 AM
May 5 15
ImmunoGen, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 11:00 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States.